Ser420
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser420  -  EPB41L3 (human)

Site Information
QAQTRRAsALIDRPA   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 2050085

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 3 , 4 , 6 , 7 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 )
Disease tissue studied:
breast cancer ( 3 , 6 ) , breast ductal carcinoma ( 3 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, surrounding tissue ( 1 ) , breast cancer, triple negative ( 1 , 3 ) , hepatocellular carcinoma, surrounding tissue ( 12 ) , lung cancer ( 6 , 9 , 10 ) , non-small cell lung cancer ( 6 , 9 , 10 ) , non-small cell large cell lung carcinoma ( 9 , 10 ) , ovarian cancer ( 3 ) , melanoma skin cancer ( 13 )
Relevant cell line - cell type - tissue:
293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 11 ) , breast ( 1 , 3 ) , BT-549 (breast cell) ( 6 ) , Calu 6 (pulmonary) ( 6 ) , Flp-In T-Rex-293 (epithelial) ( 7 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 7 ) , H2009 (pulmonary) ( 6 ) , H2077 (pulmonary) ( 6 ) , H2887 (pulmonary) ( 6 ) , H322 (pulmonary) ( 6 ) , H322M (pulmonary) ( 6 ) , HCC1359 (pulmonary) ( 6 ) , HCC1937 (breast cell) ( 6 ) , HCC2279 (pulmonary) ( 6 ) , HCC4006 (pulmonary) ( 6 ) , HeLa (cervical) ( 14 , 15 ) , hepatocyte-liver ( 12 ) , HOP62 (pulmonary) ( 6 ) , liver ( 4 ) , LOU-NH91 (squamous) ( 6 ) , MCF-7 (breast cell) ( 6 ) , MDA-MB-231 (breast cell) ( 6 ) , NCI-H1395 (pulmonary) ( 6 ) , NCI-H1568 (pulmonary) ( 6 ) , NCI-H157 (pulmonary) ( 6 ) , NCI-H1648 (pulmonary) ( 6 ) , NCI-H1666 (pulmonary) ( 6 ) , NCI-H2030 (pulmonary) ( 6 ) , NCI-H2172 (pulmonary) ( 6 ) , NCI-H3255 (pulmonary) ( 16 ) , NCI-H460 (pulmonary) ( 6 , 10 ) , NCI-H647 (pulmonary) ( 6 ) , NCI-H661 (pulmonary) ( 9 ) , ovary ( 3 ) , skin ( 13 )

Upstream Regulation
Treatments:
angiotensin_2 ( 11 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

3

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

4

Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62
24275569   Curated Info

5

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

6

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

7

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

8

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

9

Rikova K (2011) CST Curation Set: 10898; Year: 2011; Biosample/Treatment: cell line, NCI-H661/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

10

Rikova K (2011) CST Curation Set: 10894; Year: 2011; Biosample/Treatment: cell line, NCI-H460/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

11

Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53
20363803   Curated Info

12

Han G, et al. (2010) Phosphoproteome analysis of human liver tissue by long-gradient nanoflow LC coupled with multiple stage MS analysis. Electrophoresis 31, 1080-9
20166139   Curated Info

13

Tucker M (2009) CST Curation Set: 8371; Year: 2009; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

14

Zhou J (2009) CST Curation Set: 7763; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (60D12F4) Rabbit mAb Cat#: 10002
Curated Info

15

Zhou J (2009) CST Curation Set: 7760; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (60D12F4) Rabbit mAb Cat#: 10002
Curated Info

16

Moritz A (2008) CST Curation Set: 5781; Year: 2008; Biosample/Treatment: cell line, NCI-H3255/Iressa; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-PKA Substrate (RRXS/T) (100G7) Rabbit mAb Cat#: 9624, PTMScan(R) Phospho-PKA Substrate Motif (K/RK/RXS*/T*) Immunoaffinity Beads Cat#: 1984
Curated Info